Savara Inc. (SVRA)
NASDAQ: SVRA · IEX Real-Time Price · USD
4.780
-0.180 (-3.63%)
Jul 17, 2024, 4:00 PM EDT - Market closed

Company Description

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases.

The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.

Savara Inc. is headquartered in Langhorne, Pennsylvania.

Savara Inc.
Savara logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 37
CEO Matthew Pauls J.D., M.B.A.

Contact Details

Address:
6836 Bee Cave Road, Building 3, Suite 201
Austin, Texas 78746
United States
Phone 51285113796
Website savarapharma.com

Stock Details

Ticker Symbol SVRA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001160308
CUSIP Number 805111101
ISIN Number US8051111016
Employer ID 84-1318182
SIC Code 2834

Key Executives

Name Position
Matthew Pauls J.D., M.B.A. Chairman and Chief Executive Officer
David L. Lowrance CPA Chief Financial Officer, Chief Administrative Officer and Secretary
Dr. Raymond Dennis Pratt FACP, M.D. Chief Medical Officer
Robert Lutz M.B.A. Chief Operating Officer
Kate McCabe J.D. Senior Vice President and General Counsel
Anne Erickson Chief Business Officer
Brian Maurer Head of Clinical Operations
Charles LaPree Senior Vice President of Global Regulatory Affairs and Quality Assurance
Dr. Peter Clarke Ph.D. Executive Vice President of Global Technical Operations
Scott L. Wilhoit Executive Vice President of Global Commercial

Latest SEC Filings

Date Type Title
Jul 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jun 28, 2024 8-K Current Report
Jun 28, 2024 424B5 Filing
Jun 26, 2024 8-K Current Report
Jun 10, 2024 8-K/A [Amend] Current report
Jun 7, 2024 8-K Current Report
May 21, 2024 EFFECT Notice of Effectiveness
May 14, 2024 UPLOAD Filing
May 9, 2024 S-3 Registration statement under Securities Act of 1933
May 9, 2024 10-Q Quarterly Report